# Bempedoic Acid Therapy for Polycystic Kidney Disease

> **NCT07282821** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kenneth Hallows** · enrollment: 120 (estimated)

## Conditions studied

- ADPKD (Autosomal Dominant Polycystic Kidney Disease)

## Interventions

- **DRUG:** Bempedoic Acid 180 MG Oral Tablet
- **DRUG:** Placebo Capsule(s)

## Key facts

- **NCT ID:** NCT07282821
- **Lead sponsor:** Kenneth Hallows
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2029-08-31
- **Final completion:** 2030-02-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282821, "Bempedoic Acid Therapy for Polycystic Kidney Disease". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07282821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*